Shizuko Sei (MD)
NIH, Medical Officer Chemopreventive Agent Development Research Group
Shizuko Sei, MD is a physician scientist with more than 30 years of translational and clinical research experience at the National Cancer Institute (NCI). Her research interest includes tumor immunology, viral oncology, cancer vaccines, novel drug discovery and development, and precision cancer prevention. In her current capacity in the Division of Cancer Prevention (DCP), NCI, Dr. Sei manages the NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT), a peer-reviewed NCI program that facilitates preclinical development of innovative interventions for cancer prevention and interception toward clinical applications through partnerships with researchers in academia and industry. Agents developed through PREVENT are advanced to the DCP early phase clinical trial program, Cancer Prevention Clinical Trials Network (CP-CTNet). Dr. Sei has recently received approval to launch the new DCP program, Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). CAP-IT Centers will establish an agile network to undertake collaborative research that will focus on the discovery of molecularly or immunologically targeted agents for cancer prevention-interception. CAP-IT and PREVENT are expected to form a harmonized and streamlined discovery and development pipeline for innovative agents for precision cancer prevention and interception.